Recursion Pharmaceuticals (RXRX) PT Lowered to $8 at BofA Securities

May 6, 2025 5:40 AM EDT Send to a Friend
BofA Securities analyst Derik de Bruin lowered the price target on Recursion Pharmaceuticals (NASDAQ: RXRX) to $8.00 (from $10.00) while ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login